Who are PL9643 Ophthalmic Solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Otezla, Crisaborole Vehicle, Crisaborole ointment, 2%, Apremilast (CC-10004), ARQ-151 cream 0.3%, CD0271.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pl9643-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

PL9643 Ophthalmic Solution — Competitive Intelligence Brief

PL9643 Ophthalmic Solution (PL9643 Ophthalmic Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase 4 (PDE4) inhibitor. Area: Ophthalmology.

phase 3 Phosphodiesterase 4 (PDE4) inhibitor PDE4 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

PL9643 Ophthalmic Solution (PL9643 Ophthalmic Solution) — ORA, Inc.. PL9643 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production in ocular tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PL9643 Ophthalmic Solution TARGET	PL9643 Ophthalmic Solution	ORA, Inc.	phase 3	Phosphodiesterase 4 (PDE4) inhibitor	PDE4
Otezla	APREMILAST	Amgen	marketed	Phosphodiesterase 4 Inhibitor [EPC]	PDE4	2014-01-01
Crisaborole Vehicle	Crisaborole Vehicle	Pfizer	marketed	Phosphodiesterase 4 (PDE4) inhibitor	PDE4
Crisaborole ointment, 2%	Crisaborole ointment, 2%	Pfizer	marketed	Phosphodiesterase 4 (PDE4) inhibitor	PDE4
Apremilast (CC-10004)	Apremilast (CC-10004)	Virginia Clinical Research, Inc.	marketed	Phosphodiesterase 4 (PDE4) inhibitor	PDE4
ARQ-151 cream 0.3%	ARQ-151 cream 0.3%	Arcutis Biotherapeutics, Inc.	phase 3	Phosphodiesterase 4 (PDE4) inhibitor	PDE4
CD0271	CD0271	Galderma R&D	phase 3	PDE4 inhibitor	PDE4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase 4 (PDE4) inhibitor class)

Pfizer · 6 drugs in this class
Shire · 3 drugs in this class
Almirall, S.A. · 3 drugs in this class
Arcutis Biotherapeutics, Inc. · 2 drugs in this class
LEO Pharma · 2 drugs in this class
ORA, Inc. · 1 drug in this class
Tillotts Pharma AG · 1 drug in this class
AbbVie (prior sponsor, Abbott) · 1 drug in this class
Virginia Clinical Research, Inc. · 1 drug in this class
Alfasigma S.p.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PL9643 Ophthalmic Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/pl9643-ophthalmic-solution. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab